The Latest Cardiac and Vascular News
MILAN, March 2, 2021 /PRNewswire/ — Innovative Cardiovascular Solutions (ICS), a privately held medical device company developing the most complete comprehensive solution to embolic protection for structural heart and vascular interventions, announced today the success of its first European clinical cases using the next generation of the EMBLOK™ Embolic Protection System in patients […]
JACC: Clinical Electrophysiology: Findings Highlight Need to Better Classify Heart Failure Outcomes DUBLIN, March 2, 2021 /PRNewswire/ — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced new results from the landmark REVERSE trial, evaluating outcomes of cardiac resynchronization therapy (CRT) for patients with mild heart failure (HF). This new […]
ANDOVER, Mass., March 1, 2021 /PRNewswire/ — TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that the FDA’s Office of Health Technology 2 (Cardiovascular Devices) has communicated its intent to hold a Circulatory Systems Device […]
VANCOUVER and MINNEAPOLIS, March 02, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the journal Clinical Cardiology has published an article entitled, “Long-term outcomes of patients undergoing coronary sinus reducer implantation – A multicenter study.” The article, authored by Maayan Konigstein, M.D., Tel […]
SAN FRANCISCO, March 01, 2021 (GLOBE NEWSWIRE) — FibroGen, Inc. (Nasdaq: FGEN) and its partner, AstraZeneca (LSE/STO/Nasdaq: AZN), today announced that the Cardiovascular and Renal Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will hold an advisory committee (AdCom) meeting to review the new drug application for […]
LEXEO completes license of all intellectual property rights and pre-clinical data associated with Adverum Biotechnologies’ investigational Friedreich’s ataxia program Pre-clinical research licensed from academic partners and data from Adverum’s program now consolidated to support the advancement of LX2006; Phase 1 clinical trial expected to initiate in 2021 NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) — LEXEO […]
TEL AVIV, Israel, March 1, 2021 /PRNewswire/ — Vascular Grafts Solutions (VGS) Ltd. announced today receipt of marketing clearance from the Food and Drug Administration (FDA) for the VIOLA™, a new device for clampless proximal anastomosis in coronary artery bypass grafting (CABG) Neurocognitive dysfunction remains the most devastating perioperative complication of CABG […]
Successful use of the Satera™ Ablation System aims to improve chronic heart failure NEW YORK, March 1, 2021 /PRNewswire/ — Axon Therapies, a Coridea portfolio company focused on addressing a root cause of heart failure, today announced the treatment of the first patient in the randomized, controlled REBALANCE-HF IDE feasibility trial. The trial […]
The First Gene Based Project to be conducted in the Texas Rio Grande Valley EDINBURG, Texas–(BUSINESS WIRE)–Can a medical tool predict the risk of certain medications based on a patient’s genetics, and, if so, could this information lead to doctors customizing a patient’s drug therapy? The tool being studied at […]
Silence Therapeutics and Mallinckrodt Initiate Work on Third Target as Part of Ongoing RNAi Research Collaboration for Complement-Mediated Diseases Silence to receive $2 million research milestone payment Silence is also eligible to receive up to $2 billion in total milestone payments across all three targets and tiered double-digit royalties on […]
